𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Activation of signal pathways and the resistance to anti-EGFR treatment in colorectal cancer

✍ Scribed by Jiezhong Chen; Xu-Feng Huang; Andrew Katsifis

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
74 KB
Volume
111
Category
Article
ISSN
0730-2312

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Colorectal cancer is the third most common cancer with a 5‐year survival rate of less than 10%. It is caused by alterations of multiple signal pathways which are affected by both genetic and environmental factors. In some cases, EGFR is important in the carcinogenesis of colorectal cancer suggesting anti‐EGFR therapy may be a potential treatment option. However, in other cases it is not effective, which may be related to its down‐stream targeted gene mutations. KRAS is highly emphasized in the literature but other mutations like Src, PIK3CA, and BRAF may also be important. Furthermore, obesity may decrease the effectiveness of anti‐EGFR treatment as it increases the risk factors for colorectal cancer. Using next‐generation sequencing technology, it may be possible to identify all gene mutations in an individual with colorectal cancer. Therefore, gene mutations affecting anti‐EGFR therapy in colorectal cancer patients can be identified. J. Cell. Biochem. 111: 1082–1086, 2010. © 2010 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Additional value of EGFR downstream sign
Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer
✍ Geraldine Perkins; Astrid Lièvre; Carole Ramacci; Tchao Méatchi; Aurélien de Rey 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 393 KB

## Abstract __KRAS__ mutations are a strong predictive marker of resistance to anti‐epidermal growth factor receptor (EGFR) antibodies in advanced colorectal cancer (CRC) but only a subset of wild‐type (WT) __KRAS__ patients are responders, suggesting the existence of additional markers of resistan

The MEK/MAPK pathway is involved in the
The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib
✍ Nicola Normanno; Antonella De Luca; Monica R. Maiello; Manuela Campiglio; Maria 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 287 KB 👁 1 views

## Abstract We investigated the role of the MEK/MAPK pathway in the sensitivity/resistance of breast carcinoma cells to the EGFR tyrosine kinase inhibitor gefitinib (IRESSA). We assessed the effects of gefitinib on the growth of three breast cancer cell lines that showed high (SK‐Br‐3; IC~50~ 4 µM)

Isothiocyanate sulforaphane inhibits pro
Isothiocyanate sulforaphane inhibits protooncogenic ornithine decarboxylase activity in colorectal cancer cells via induction of the TGF-β/Smad signaling pathway
✍ Bettina M. Kaminski; Stefan M. Loitsch; Meike J. Ochs; Kerstin C. Reuter; Dieter 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 450 KB

## Abstract **Scope:** The objective of this study was to elucidate molecular mechanisms behind the antitumor activities of the isothiocyanate sulforaphane (SFN) in colorectal cancer cells. **Methods and results:** Cell growth was determined by BrdU incorporation and crystal violet staining. Prote

Activation of Src and Src-associated sig
Activation of Src and Src-associated signaling pathways in relation to hypoxia in human cancer xenograft models
✍ Nhu-An Pham; Joao M.M.M. Magalhaes; Trevor Do; Joerg Schwock; Neesha Dhani; Ping 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 French ⚖ 358 KB 👁 1 views

## Abstract The hypoxic response __in vitro__ involves alterations in signaling proteins, including Src, STAT3 and AKT that are considered to be broadly pro‐survival. The involvement of these signaling proteins in the hypoxic microenviroments that occur in solid tumors was investigated by the use o

Intestinal epithelial cancer cell anoiki
Intestinal epithelial cancer cell anoikis resistance: EGFR-mediated sustained activation of Src overrides Fak-dependent signaling to MEK/Erk and/or PI3-K/Akt-1
✍ Marie-Josée Demers; Sonya Thibodeau; Dominique Noël; Naoya Fujita; Takashi Tsuru 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 527 KB

## Abstract Herein, we investigated the survival roles of Fak, Src, MEK/Erk, and PI3‐K/Akt‐1 in intestinal epithelial cancer cells (HCT116, HT29, and T84), in comparison to undifferentiated and differentiated intestinal epithelial cells (IECs). We report that: (1) cancer cells display striking anoi

Colorectal cancers show distinct mutatio
Colorectal cancers show distinct mutation spectra in members of the canonical WNT signaling pathway according to their anatomical location and type of genetic instability
✍ Cristina Albuquerque; Célia Baltazar; Bruno Filipe; Filipa Penha; Teresa Pereira 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 962 KB

## Abstract It is unclear whether the mutation spectra in WNT genes vary among distinct types of colorectal tumors. We have analyzed mutations in specific WNT genes in a cohort of 52 colorectal tumors and performed a meta‐analysis of previous studies. Notably, significant differences were found amo